Lucintel anticipates that North America Pacific will be the fastest growing region in the liquid biopsy market


   October 18, 2019
According to a new market report published by Lucintel, the future of the liquid biopsy market looks promising with opportunities in the reference laboratories, hospitals, physician laboratories, and academic and research centers end use segments. The liquid biopsy market is expected to grow with a CAGR of 23% from 2019 to 2024. The major drivers for this market are increasing prevalence of cancer, increasing preference for noninvasive procedures, rising emphasis on personalized medicine, and availability of funding for liquid biopsy research and development.

To download free sample and PDF brochure please go to https://www.lucintel.com/liquid-biopsy-market.aspx and click report brochure/download sample

Liquid biopsy tests are executed to understand the molecular aspects of early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring orthopedics applications. Therapy selection is the largest application segment of the liquid biopsy market.

North America will remain the largest region over the forecast period due to recent regulatory approvals by CE for commercial use of these liquid biopsy tests.

Biocept, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini-Silicon Biosystems, Trovagene, Guardant Health, Mdxhealth, Genomic Health, Raindance Technologies, Thermo Fisher Scientific, and Illumina are among the major players of liquid biopsy.

Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the liquid biopsy market by product, circulating biomarker, clinical application, application, end use, and region. Lucintel has prepared a comprehensive research report titled "Liquid Biopsy Market 2019-2024: Trends, Forecast, and Opportunity Analysis". The Lucintel report serves as a catalyst for growth strategy as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the liquid biopsy market by product, circulating biomarker, clinical application, application, end use, and region as follows:

By Product [$M shipment analysis for 2013 – 2024]:



  • Assays Kits


  • Instruments


  • Services


By Circulating Biomarker [$M shipment analysis for 2013 – 2024]:



  • Circulating Tumor Cells (CTCs)


  • Circulating Tumor DNA (ctDNA)


  • Cell-Free DNA (cfDNA)


  • Extracellular Vesicles (EVs)


  • Other Circulating Biomarkers


By Clinical Application [$M shipment analysis for 2013 – 2024]:



  • Early Cancer Screening




  • Therapy Selection


  • Treatment Monitoring


  • Recurrence Monitoring Orthopedics


By Application [$M shipment analysis for 2013 – 2024]:



  • Oncology


  • Lung Cancer


  • Breast Cancer


  • Colorectal Cancer


  • Prostate Cancer


  • Liver Cancer


  • Other Cancers


  • Non-Cancer


By End Use [$M shipment analysis for 2013 – 2024]:



  • Reference Laboratories


  • Hospitals and Physician Laboratories


  • Academic and Research Centers


  • Other End Users


By Region [$M shipment analysis for 2013 – 2024]:



  • North America


    • United States


    • Canada


    • Mexico




  • Europe


    • United Kingdom


    • Germany


    • France


    • Italy


    • Spain




  • Asia-Pacific


    • China


    • India


    • Japan




  • ROW


    • Brazil




This 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link https://www.lucintel.com/liquid-biopsy-market.aspx or helpdesk@lucintel.com.

About Lucintel

Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.


Lucintel Corporate Customers

Market Entry, M & A, Opportunity Screening,...

Private Equity Customers

Buy Side Services (target screening, due diligence, ..)

Market Research Reports

Aerospace & Defense [51]
Chemical [258]
Composites & Advanced Materials [159]
Construction & Industrial [68]
Consumer and Retail [120]
Economic Analysis [86]
Energy & Utility [73]
Finance & Services [10]
Healthcare [62]
Media & Entertainment [16]
Metals & Mining [17]
Technology & Telecommunication [162]
Transportation [140]

Customer Quotes

"With more than 20 years experience in the industry, this is the first time we have come across such an extensive market analysis for our industry." Ven Cote, CEO, ZCL

"The insights we gained from Lucintel work helped with our business plan…a wonderful professional job…" Mike Jackson, Stahlin

"The report from Lucintel is useful not only for business planners, but also for the technology officers wanting to create a roadmap …" Dr. Giulio Ranzo, Booz Allen

"The information is so comprehensive, it has allowed us to identify & focus our business development efforts. It saved months of leg-work." Bill Barz, L&L Products

"We bought Lucintel report because it is the best report about our industry…a complete and appropriate analysis." Cesare Andrenacci, Ferretti

Quick Query

Lucintel Insights in News

Follow us on